nuclear receptor subfamily 0 group B member 2Genealiases: SHP · SHP1
Q-omics provides the consensus-scored NR0B2 profile across patient tissues and cancer cell-line models. NR0B2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, NR0B2 is differentially expressed in 11, with the highest sampling consensus in KIRP. Additionally, NR0B2 RNA expression shows 11,753 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, KIRP, and TGCT as cancer lineages where NR0B2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NR0B2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NR0B2 survival associations across molecular data types. NR0B2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NR0B2 RNA expression–survival associations across cancer types. High NR0B2 expression shows unfavorable associations in LUSC, HNSC, LGG and KIRC, but favorable associations in ACC and LUAD. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for NR0B2 RNA expression.
This table summarizes NR0B2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for NR0B2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NR0B2 shows lower tumor expression in KIRP, KIRC, LUSC, LUAD and LIHC and higher tumor expression in COAD. The KIRP box plot shows higher NR0B2 RNA expression in normal versus tumor tissue (log2 FC = −4.769, t-test p < 0.001).
This table shows molecular features associated with NR0B2 in patient tissues and cancer cell lines. In patient samples, NR0B2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, NR0B2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and LUNG_SCLC.
